Browse EX-10 agreements

Mittie Doyle, M.D.

[Email]

9/15/2026

Dear Mittie:

We are very pleased to invite you to join the board of directors (the “Board”) of Talawar Tx Inc. (the “Company”) as a director, which appointment shall occur after the Company has obtained the requisite corporate approvals. It is anticipated that your appointment will be effective October 1, 2026.

…

Susannah Gray

[Email]

9/15/2026

Dear Susannah:

We are very pleased to invite you to join the board of directors (the “Board”) of Talawar Tx Inc. (the “Company”) as a director, which appointment shall occur after the Company has obtained the requisite corporate approvals. It is anticipated that your appointment will be effective October 1, 2026. In addition, in connection with the Company’s pending business combination with JATT II Acquisition Corp (the “Business Combination”), the Board expects to form an audit committee of the Board (the “Audit Committee”) and, subject to requisite corporate approvals, is expected to appoint you as Chair of the Audit Committee.

…

TALAWAR TX INC.

May 29, 2026

Praveen Tipirneni

[Email]

Dear Praveen:

We are very pleased to invite you to join the board of directors (the “Board”) of Talawar Tx Inc. (the “Company”) as a director.

Following your appointment to the Board, which shall occur after the Company has obtained the requisite corporate approvals for such appointment, you will be eligible to receive equity awards in the Company under the terms of the Company’s 2026 Equity Incentive Plan (the “2026 Plan”).

…

12707 High Bluff Drive, Suite 200

San Diego, CA 92130

September 25, 2026

Herb C. Cross

[***]

Re:	**Employment Terms **

Dear Herb,

Avenzo Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Chief Financial Officer on the terms and conditions set forth in this letter agreement (the “Agreement”).

…

Execution Version THIRD AMENDMENT THIS THIRD AMENDMENT, dated as of August 14, 2026 (this "Agreement"), is entered into by and among TENAX AEROSPACE HOLDINGS, LLC, a Delaware limited liability company (the "Borrower"), the Guarantors party hereto, the Lenders party hereto, REGIONS BANK, as Administrative Agent, and REGIONS EQUIPMENT FINANCE CORPORATION, as Collateral Agent. RECITALS WHEREAS, senior secured credit facilities, consisting of a revolving credit facility, a term loan facility and a delay draw term loan facility, were established pursuant to that certain Second Amended and Restated Credit Agreement dated as of January 23, 2024 (as amended, modified, extended, renewed or replaced, the "Credit Agreement") among the Borrower, the Subsidiaries and Affiliates identified therein, as Guarantors, the Lenders identified therein, the Administrative Agent and the Collateral Agent; WHEREAS, the Borrower has requested that the Credit Agreement be amended as set forth herein; and WHEREAS, the Lenders, the Administrative Agent and the Collateral Agent are willing to amend the Credit Agre

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED

BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE

TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Execution Version

Confidential

LICENSE AGREEMENT

This** LICENSE AGREEMENT** (the “Agreement”) is made effective on June 15, 2026 (the “Effective Date”), by and between Avere Therapeutics, Inc., a Delaware corporation, having a place of business at 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428 (“Avere”) and Shanghai Hansoh Biomedical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Hansoh”, with Avere, each a “Party”).

RECITALS

(A)Hansoh is a biotechnology company developing oral peptide IL-23 receptor antagonists for the treatment of psoriasis and inflammatory bowel disease.

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Execution Version

Confidential

CLINICAL SUPPLY AGREEMENT

This Clinical Supply Agreement (this “Agreement”) is entered into as of September 23, 2026 (the “Effective Date”), by and between Avere Therapeutics, Inc., a Delaware corporation having its principal place of business at 1500 District Avenue, Burlington, MA  01803 1500 District Avenue, Burlington, MA  01803 (“Avere”) on the one hand, and Jiangsu Hansoh Pharmaceutical Group Company Ltd., a corporation incorporated under the laws of China having its principal place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyungang, Jiangsu, China (“Jiangsu Hansoh”) and Shanghai Hansoh Biomedical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Shanghai Hansoh” , and together with Jiangsu Hansoh, “Hansoh”), on the other hand. Avere and Hansoh are each referred to in th

…

** **

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (this “Agreement”), dated as of September __, 2026 (the “Effective Date”), is entered into by and between Agility Robotics, Inc., a Delaware corporation (including any successors or permitted assigns, the “Company”), and [____] (“Executive” and, together with the Company, the “Parties”).

WHEREAS, the Company previously engaged the Executive to provide services to the Company pursuant to the terms and conditions of an [Offer Letter]/[Executive Employment Agreement] by and between Company and Executive, dated [_____] (the “Prior Agreement”);

WHEREAS, Company wishes to execute an executive employment agreement (this “Agreement”) with Executive pursuant to which Executive will continue to provide services to the Company subject to the terms and conditions of this Agreement effective as of Effective Date;

…

** **

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT COVERING SUCH TRANSACTION, OR (B) SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT.

Issue Date: October 10, 2022

** **

AGILITY ROBOTICS INC.

WARRANT TO PURCHASE SHARES

…

FORM OF INDEMNIFICATION And Advancement AGREEMENT

This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Agility Robotics, Inc., a Delaware corporation (the “Company”), and ______________, a member of the Board of Directors / an officer of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering indemnification and advancement of expenses.

RECITALS

WHEREAS, the Board of Directors of the Company (the “Board”) believes that highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification and advancement of expenses against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

…

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL.

MASTER COOPERATION AGREEMENT

Contract No: KIKA-IFPC-20250902

Date of Signing: September 29, 2025

Party A: VISRISCO TECHNOLOGY LIMITED

Address: RM 509, 5/F,THE CLOUD,111 TUNG CHAU STREET,TAI KOK TSUI, KOWLOON,

HONG KONG

Company registration number: 2122505

Party B: KIKA TECHNOLOGY INC.

Address: P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman,

KY1-1205 Cayman Islands

Company registration number: 425046

Based on the principles of equality, mutual benefit, common development, complementary advantages, and equivalent compensation, Party A and Party B have mutually agreed upon the following terms regarding Party A’s provision of promotional services on Party B’s platform through friendly consultation:

Article 1 Definitions

…

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL.

Framework Cooperation Agreement

This Framework Cooperation Agreement (hereinafter referred to as this “Agreement”) is entered into by and between the following parties on September 26, 2025:

Party A: MATINALEOUS TECHNOLOGY LIMITED

Company Registration Number: 2056563

Party B: HongKong Time Point Technology Co., Limited

Company Registration Number: 75862015

In view of the resources and business advantages possessed by Party A and Party B in their respective industries, and for the purpose of jointly advancing market cooperation between both parties, Party A and Party B, following the principles of equality and voluntariness, have entered into this Framework Agreement through friendly consultation to set forth the fundamental terms of their cooperation.

…